Target Information

Target General Infomation
Target ID
T47610
Former ID
TTDS00501
Target Name
Interleukin-11 receptor alpha chain
Gene Name
IL11RA
Synonyms
IL-11R-alpha; IL-11RA; IL11RA
Target Type
Successful
Disease Prostate cancer [ICD9: 185; ICD10: C61]
Severe thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0]
Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0]
Function
Receptor for interleukin-11. The receptor systems for IL6, LIF, OSM, CNTF, IL11 and CT1 can utilize IL6ST for initiating signal transmission. The IL11/IL11RA/IL6ST complex may be involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells. Essential for the normal development of craniofacial bones and teeth. Restricts suture fusion and tooth number.
BioChemical Class
Type I cytokine receptor
UniProt ID
Q14626
Sequence
MSSSCSGLSRVLVAVATALVSASSPCPQAWGPPGVQYGQPGRSVKLCCPGVTAGDPVSWF
RDGEPKLLQGPDSGLGHELVLAQADSTDEGTYICQTLDGALGGTVTLQLGYPPARPVVSC
QAADYENFSCTWSPSQISGLPTRYLTSYRKKTVLGADSQRRSPSTGPWPCPQDPLGAARC
VVHGAEFWSQYRINVTEVNPLGASTRLLDVSLQSILRPDPPQGLRVESVPGYPRRLRASW
TYPASWPCQPHFLLKFRLQYRPAQHPAWSTVEPAGLEEVITDAVAGLPHAVRVSARDFLD
AGTWSTWSPEAWGTPSTGTIPKEIPAWGQLHTQPEVEPQVDSPAPPRPSLQPHPRLLDHR
DSVEQVAVLASLGILSFLGLVAGALALGLWLRLRRGGKDGSPKPGFLASVIPVDRRPGAP
NL
Drugs and Mode of Action
Drug(s) Oprelvekin Drug Info Approved Severe thrombocytopenia [536361], [542002]
UNI-rhIL-11 Drug Info Phase 3 Thrombocytopenia [524018]
BMTP-11 Drug Info Phase 1 Prostate cancer [522624]
Modulator BMTP-11 Drug Info [533180]
UNI-rhIL-11 Drug Info [526485]
Binder Oprelvekin Drug Info [536534]
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM)
TEP EXP Info
Pathways
KEGG Pathway Cytokine-cytokine receptor interaction
Jak-STAT signaling pathway
Hematopoietic cell lineage
PANTHER Pathway Interleukin signaling pathway
WikiPathways Interleukin-11 Signaling Pathway
References
Ref 522624ClinicalTrials.gov (NCT00872157) BMTP-11 in Patients With Castrate-Resistant Prostate Cancer With Bone Mets. U.S. National Institutes of Health.
Ref 524018ClinicalTrials.gov (NCT01663441) A Phase ??Study of Genetically Modified Recombinant Human Interleukin-11. U.S. National Institutes of Health.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 542002(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6971).
Ref 526485Clinical study of rhIL-11 for prevention and treatment of chemotherapy-induced thrombocytopenia. Ai Zheng. 2002 Aug;21(8):892-5.
Ref 533180Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. Clin Cancer Res. 2015 Jul 1;21(13):3041-51.
Ref 536534Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.